Drug intelligence / Profile preview

tau targeting RNA aptamer

Development stage
Preclinical
Modality
RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

Tau targeting RNA aptamers are single-stranded oligonucleotides specifically designed to bind to the human tau protein, a microtubule-associated protein implicated in neurodegenerative diseases known as tauopathies, including Alzheimer's disease. These RNA aptamers inhibit the oligomerization of tau, which is considered a critical step in the formation of toxic aggregates associated with neuronal dysfunction and cell death. By binding to tau and preventing its assembly into oligomers, these aptamers have demonstrated neuroprotective effects in vitro and in cellular models by reducing proteotoxic stress, alleviating synthetic tau oligomer-mediated neurotoxicity, and preserving dendritic spine density. The approach represents a targeted strategy for modulating pathogenic processes underlying Alzheimer's disease and related disorders[2][1][5].

Other names
tau-targeting RNA aptamerRNA aptamer against tautau oligomerization-inhibiting RNA aptamer
02

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on tau targeting RNA aptamer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tau targeting RNA aptamer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call